header logo image


Page 1,040«..1020..1,0391,0401,0411,042..1,0501,060..»

Udupi: Kishen Gangolli – Blindness is no hindrance to this chess champ – Daijiworld.com

April 3rd, 2017 3:45 am

Pics: Umesh Marpalli Daijiworld Media Network - Udupi (SP)

Udupi, Apr 2: Kishen Gangolli from Kundapurcame out with the gold medal in the IBCA Asian Chess Championship for the blind held at Manipal which came to an end on Friday March 31. Kishan, who ended the eighth round against Aryan B Joshi from Maharasthra on Friday through a draw, was declared winner for having collected maximum of seven out of eight possible points. Born blind, Kishen has never accepted blindness as a shortcoming.

Kishen now aims atchess Olympiad for the blind being held in June this year at Macedonia. He wants to win gold medal for the team in addition willing gold medal for himself. In 2012, he had participated in the chess Olympiad held in Chennai and won gold medal. India, the best performance of which was 16th place in Olympiad till then, won fifth spot in that competition. Kishen has been working hard for himself and the country since then.

Indian chess team now comprises Kishan Gangolli, Makwan Ashwin K of Gujarat, who got silver medal this time, Soundarya Kumar Pradhan of Odisha and Aryan Joshi and Patil Shjrish from Maharashtra.

Kishan (25) is from Gangolli in Kundapur taluk. His father, Raveendra, employed in Canara Bank, has settled down in Shivamogga. His mother works as beautician in Shivamogga. Kishen happens to be the only child of his parents. He has secured MA in economics from Kuvempu University with second rank.

Kishen took to chess seriously when in sixth standard with the support of his maternal uncle. He began to participate in chess competitions for the blind in 2011. He was initially trained by Krishna Udupa from Shivamogga who happens to be another blind chess player.

Kishen usually mingles with everyone without unduly publicizing his handicap or seeking any undue favour. Kishen feels that he could come so far because of his habit of overlooking his blindness and the determination to do more in sports and life.

Continue reading here:
Udupi: Kishen Gangolli - Blindness is no hindrance to this chess champ - Daijiworld.com

Read More...

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non … – Business Wire (press release)

April 3rd, 2017 3:44 am

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation entitled, Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 basket study, was presented as a plenary session by David Hyman, M.D., Director of Developmental Therapeutics at Memorial Sloan Kettering Cancer Center (MSK), and principal investigator of the trial.

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating HER2 or HER3 mutations. All patients received loperamide (16 mg per day initially) prophylactically for the first cycle of treatment in order to reduce the neratinib-related diarrhea.

Included in the presentation were data on 141 patients enrolled in the neratinib monotherapy arm of the trial, including 124 patients with HER2 mutations and 17 patients with HER3 mutations. This included patients with 21 unique tumor types, with the most common being breast, lung, bladder and colorectal cancer. There were also 30 distinct HER2 and 12 distinct HER3 mutations observed among these patients, with the most frequent HER2 variants involving S310, L755, A755_G776insYVMA and V777.

In the HER2-mutant cohort, clinical responses were observed in tumors with S310, L755, V777, P780_Y781insGSP and A775_G776insYVMA mutations. When stratified by tumor type, responses were observed in patients with breast, cervical, biliary, salivary and non-small-cell lung cancers, which led to cohort expansions in these tumor types. No activity was observed in the HER3-mutant cohort. A more detailed presentation of the data is presented in Table 1 below and a copy of the full presentation is available on the Puma Biotechnology website.

HER2mut

HER2mut

HER2mut

HER2mut

HER2mut

HER2mut

HER3mut

Lung

(95% CI)

rate, n (%)

(95% CI)

20.1

(95% CI)

(0.5--NA)

The neratinib safety profile observed in the SUMMIT study is consistent with that observed previously in metastatic patients with HER2 amplified tumors. With anti-diarrheal prophylaxis and management, diarrhea was not a treatment-limiting side effect in SUMMIT. The interim safety results of the study showed that the most frequently observed adverse event was diarrhea. For the 141 patients enrolled in the neratinib monotherapy arm with safety data available, 31 patients (22%) reported grade 3 diarrhea. The median duration of grade 3 diarrhea for those patients was 2 days. 4 patients (2.8%) permanently discontinued neratinib due to diarrhea and 21 patients (14.9%) temporarily discontinued neratinib due to diarrhea and then restarted after the diarrhea subsided.

Dr. David Hyman stated, "Neratinib showed signs of clinical activity in several of the cohorts in the SUMMIT trial. The safety profile of the drug was manageable and the diarrhea was not treatment-limiting with appropriate prophylaxis and management. We look forward to completing enrollment in the ongoing cohorts in the study and continuing to utilize the basket trial design to explore possible treatment options for these select patient populations.

"The basket-trial design we are utilizing for SUMMIT is enabling us to evaluate the clinical potential of neratinib in patients with specific mutation-types rather than limiting exploration to one tumor type at a time. It is an efficient approach that is generating clinically meaningful information to guide targeted therapy across a broad spectrum of tumor types with HER mutations, including in patients with rare tumors who may not otherwise have access to investigational therapies, said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. We are very pleased with the preliminary activity seen with neratinib in the SUMMIT trial. We look forward to advancing this targeted compound into further clinical development in multiple HER2 mutant tumor types, both as monotherapy and in novel combinations."

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2. Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements, including statements regarding the development of the Companys drug candidates. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Company's dependence on PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company's drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Company's products; the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Company's dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

More here:
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non ... - Business Wire (press release)

Read More...

Free Tucson lecture to focus on arthritis-heart disease connection – Arizona Daily Star

April 3rd, 2017 3:44 am

The free talk, Listen to Your Heart A Cardiologists Inside Look at Cardiovascular Health, Inflammation and Arthritis, is scheduled for 6 p.m. Wednesday, April 5 in DuVal Auditorium at Banner- University Medical Center Tucson, 1501 N. Campbell Ave.

University of Arizona Sarver Heart Center cardiologist Dr. Charles Katzenberg, is expected to discuss cardiovascular risk and its relationship with inflammation.

Topics will include the key role of the inflammatory process in arthritis-related diseases; the subsequent increases in the risk of diabetes, hypertension and underlying cardiac disease, and research initiatives on the horizon.

Katzenberg will also explore the role of an anti-inflammatory diet and discuss how specific preventive measures can help reduce cardiovascular risk.

Parking is available in the Banner-University Medical Center Tucson visitor/patient parking garage just south of the hospitals main entrance. Bring your parking ticket to the lecture to be validated for free parking.

Contact health reporter Stephanie Innes at 573-4134 or email sinnes@tucson.com. On Twitter:

@stephanieinnes

Original post:
Free Tucson lecture to focus on arthritis-heart disease connection - Arizona Daily Star

Read More...

Premier Wellness Group Offers Regenerative Cell Therapy for Knee … – GlobeNewswire (press release)

April 3rd, 2017 3:43 am

April 02, 2017 10:00 ET | Source: Premier Wellness Group

CAPE CORAL, Fla., April 02, 2017 (GLOBE NEWSWIRE) -- Regenerative cell therapy offers residents a way to reduce pain and support their bodys healing process from auto accident injuries, personal injuries, and sports injuries. Painful acute and chronic injuries can be healed using amniotic stem cells. Patients can experience pain relief without drugs with regenerative cell therapy injections that use the growth factors in amniotic stem cells to stimulate healing. Regenerative cell therapy can allow patients a safe form of pain relief and reduce their reliance on pain medications. Regenerative cell therapy is available as part of a patients individualized treatment program by the medical team at Premier Wellness Group.

Regenerative stem cell therapy offers pain relief for auto accident injuries and personal injuries, such as patients dealing with shoulder pain, knee pain, and back pain. Stem cells are a powerful tool for healing. The specialized cells begin as blank cells in that they can be used to regrow any cell needed. It is possible to regrow new cells, muscle, and tissue without surgery. Uninjured stem cells are injected into a targeted area and develop into needed cells. Stem cell therapy supports the bodys own healing process, allowing patients to benefit from injury management without surgery or painkillers.

Patients do not need to worry about any reactions due to rejection, and the amniotic regenerative stem cell therapy process is the least evasive of other forms of stem cell therapy. Patients need little, if any, downtime and stem cell therapy complements chiropractic treatments, massage therapy, nutritional counseling, and corrective exercises to guide the body back into a state of wellness. Stem cell therapy can reduce inflammation, promote healing, and increase range of motion.

We are pleased to provide patients with a natural form of pain relief and rehabilitation that takes into account the bodys own ability to heal itself, said Dr. Patrick King. Regenerative cell therapy requires no surgery- only injections performed by our physician. Stem cell therapy is safe and most patients require no downtime. We invite residents suffering from pain or trauma due to a car accident injury, sports injury, or personal injury to contact our team to learn more about this advanced therapy for healing and recovery.

Dr. Patrick King, clinic director and owner of Premier Wellness Group, has served the chiropractic and rehabilitation needs of residents of Cape Coral, Fort Myers, and surrounding communities for more than 15 years. Patients have made Premier Wellness Group their destination for drug-free, non-surgical pain relief, and rehabilitation. Services at Premier Wellness Group include regenerative cell therapy, trigger point therapy, corrective exercises, lifestyle recommendations, and chiropractic care.

Call (239) 573-7988 to learn more about Cape Coral regenerative cell therapy for knee and shoulder pain relief, or to schedule an appointment. Visit http://www.mypremierwellnessgroup.com/ for additional details.

Related Articles

Read more from the original source:
Premier Wellness Group Offers Regenerative Cell Therapy for Knee ... - GlobeNewswire (press release)

Read More...

The risks of unproven stem cell treatments – Radio New Zealand

April 3rd, 2017 3:43 am

An expert in stem cell treatment is warning of dodgy operators in New Zealand offering unproven and potentially dangerous treatments.

Auckland University Medical School lecturerBronwen Connor's warning comesafter arecently-released scientific paper documented a case of three women in the United States who were blinded by an experimental treatment for macular degeneration.

She said many people had stem cell therapy in the belief it was scientifically valid, but that was not often the case.

Dr Connor told Nine To Noon the cells used most often for the treatments were known as adipose cells, which were obtained from fat tissue in the body. They were popular because they couldbe obtained from a patientby liposuction, isolated out, then re-injected for supposed therapeutic use.

"Adipose stem cells obviously have a very important job, but predominantly their job is to make bone and cartilage. They also do have some anti-inflammatory properties. But they, to date, have not been shown to have any potential or ability to generate brain cells, for example, or new kidney cells or heart cells."

Websites for clinics offering the treatments listed up to 20 or 30 different types of diseases, disorders or conditions that one source of cells could supposedly treat. That was worrying, she said.

Adipose stem cells might be the right choice to help repair cartilage damage in the knee. "However, it wouldn't be your stem cell choice if you ... had Parkinson's disease and you were going to try and replace some of those lost cells in your brain."

Dr Connor said people needed to be sceptical and check if, for example, there hadbeen any human clinical trials involving the treatment.

"There are always dangers around treatments that we haven't taken out long-term and which there haven't been sufficient rigorous human clinical trials undertaken [on]. This is the purpose of clinical trials, to see what is the safety aspect and the efficacy of this procedure."

She advisedpeople to think about it in terms of medicines and drugs that people were used to taking, like aspirin. "If you inject yourself with a stem cell population and you have a bad side effect, you can't get those cells out. So ... we really need to know what those cells are going to do long-term and what any potential risk is, because they cannot be retrieved."

The Ministry of Health did not regulate stem cell therapy in this country because the cells were not regarded as medicine. She said it was a grey area, because cells were being taken from a patient and re-injected into the same patient with their consent. "But really, moving forward in the next 10 to 20 years, we're going to see more and more of these type of therapies that don't involve a pill or a tablet or our traditional thought of a medicine, and we really need to get regulations around that type of therapy."

She had spoken to people who paid large sums of money for the treatments.

"When I questioned them a little bit more ... did it help, they would sort of sheepishly say 'well, no not really'."

Dr Connor said clinics offering the treatments often emphasised the benefits according to the scientific literature, but it might be benefits in animals - not from human trials. She wanted quality control addressed and standardisedprocedures, along with safety and efficacy.

Dr Connor wanted to see clinical trials of many of the therapies,as they hadpotential. "Our fear is that, as with the three women with the macular degeneration, is that anything that goes wrong will really hinder the field because people will just see it as stem cell therapy."

Originally posted here:
The risks of unproven stem cell treatments - Radio New Zealand

Read More...

Diabetes: Kids and Type 1 Diabetes – myfox8.com

April 1st, 2017 9:50 pm

myfox8.com
Diabetes: Kids and Type 1 Diabetes
myfox8.com
The incidence of type 1 diabetes, previously known as juvenile diabetes, has been steadily rising in the United States. Type 1 diabetes is an auto-immune disease in which the body is destroying the cells in the pancreas that make insulin, and is often ...

More here:
Diabetes: Kids and Type 1 Diabetes - myfox8.com

Read More...

Cone Health clinic fights diabetes in Rockingham County – Greensboro News & Record

April 1st, 2017 9:50 pm

REIDSVILLE Since Fall 2015, the Cone Health Nutrition and Diabetes Management Center in Reidsville has been tackling diabetes head on as the first clinic of its kind in Rockingham County.

We provide education to patients that have diabetes and other medical problems, said Penny Crumpton, registered dietician and certified diabetes educator with the center. Our goal is to try to help provide knowledge and education to those who need assistance in helping improve their diabetes and reducing the complications that we know diabetes can cause.

According to Crumpton, diabetes is a serious issue in Rockingham County.

The rates of diabetes are extremely high in Rockingham County so the need is very great in terms of reaching out to those who are most in need, Crumpton said. While we educate patients with diabetes, we also try to reach out and address the epidemic of pre-diabetes that certainly puts patients at high risk for developing diabetes down the road.

Uncontrolled diabetes can lead to long time and irreversible problems, including damage to the eyes and kidneys, cardiovascular complications and peripheral vascular disease.

In the year and a half since the center opened, Crumpton and Gebre Nida, the centers endocrinologist, have been working with patients to help address those problems.

At the office, patients can come for one-on-one counseling sessions to discuss their situation or guests can attend free community education classes at 9 a.m. on the first and third Monday of the month at Annie Penn Hospital.

Yet with diabetes a prevalent problem in the area, Crumpton and Nida are pushing for awareness through the diabetes task force. This task force unites local health care providers and other community stakeholders around making a change.

Were working through the diabetes task force to try to increase the public awareness of the rates of diabetes and getting the resources more visible to the community and being able to connect patients with resources, Crumpton said.

For Norbert Hector, the center has already made a difference in his life after visiting the center for the first time in February.

According to Hector, he was diagnosed with diabetes about 20 years ago and has been on insulin for about 11 years.

About two months ago, my readings became very erratic, and so I called (my primary care provider) and tried to do some self-adjusting and really messed it up, he said.

His doctor referred him to Nida at the Cone Health Nutrition and Diabetes Management Center in Reidsville.

As a diabetic, I had been concerned about it, Hector said. I know its a progressive disease, and Ive watched other diabetics including my brother get progressively worse and my brother eventually died.

By following the directions given to him by Nida and Crumpton and with the support of his wife, Hector has already seen improvements in his condition.

I feel a lot more optimistic now than I did two months ago, he said.

As the center creates more stories like Hectors and the practice builds, they will consider adding another endocrinologist and diabetes educator to widen the centers impact and reach the growing population affected by diabetes.

For more information about the Cone Health Nutrition and Diabetes Management Center in Reidsville, call 336-951-6070 or visit the center at 1107 S. Main St., Reidsville.

You have nothing to lose and whole lot to gain, Hector said. Give it a shot.

Contact JustynMelrose at (336) 349 -4331, ext. 6140 and follow@jljmelrose on Twitter.

View original post here:
Cone Health clinic fights diabetes in Rockingham County - Greensboro News & Record

Read More...

Youth with diabetes need vision loss screening | Reuters – Reuters

April 1st, 2017 9:50 pm

(Reuters Health) Diabetes can lead to blindness, but children and teens with diabetes may not receive recommended eye exams in the years following their diagnosis, a U.S. study suggests.

Researchers found that just 65 percent of youth with type 1 diabetes and 42 percent of those with type 2 diabetes had vision-loss screening within six years of their diabetes diagnosis.

More youth now than ever are being diagnosed with diabetes. By 2050, the prevalence with type 1 will triple and the prevalence with type 2 will quadruple, with the greatest increase in minority populations, said lead study author Dr. Sophia Wang of the University of Michigan Medical School in Ann Arbor.

The American Academy of Ophthalmology recommends screening for diabetic retinopathy five years after an initial diabetes diagnosis for youth with type 1 diabetes while the American Diabetes Association and the American Academy of Pediatrics recommend screening within three to five years. For kids with type 2 diabetes, screening is recommended at diagnosis.

Diabetic retinopathy is a complication of diabetes that may not have symptoms in early stages but can progress to vision loss. The damage to the retina of the eye results from damage to tiny blood vessels that affects other parts of the body as well.

About half of people with retinopathy develop diabetic macular edema, a fluid build-up in the retina, or glaucoma.

Diabetic retinopathy is the number one cause of vision loss in ages 20-74, so screening is an important component of diabetes care, Wang told Reuters Health by email.

To see how many kids with diabetes are getting the recommended screening, Wang and colleagues analyzed data from a national managed care network, which included more than 5,400 youth under age 21 with type 1 diabetes and 7,200 with type 2 diabetes.

Overall, researchers found that about 4,000 kids, or 31 percent, had an eye exam.

Those with type 1 diabetes were more likely to have had an eye exam compared with those who had type 2 diabetes, the study team reports in JAMA Ophthalmology . White and Asian youth were more likely to have had exams than black and Latino youth. Those with a higher household net worth were also more likely to receive an eye exam compared with those in lower-income households.

Despite the fact that all the youth in our study possessed health insurance, we found disparities by race and family affluence, suggesting that they may be particularly at risk, Wang said.

In the study, 11 percent of black children and teens and 18 percent of Latino youth were less likely to undergo an eye exam compared to white kids. Younger patients were also less likely to receive an exam than older ones.

We must educate adolescents and caregivers on the importance of screening to improve care coordination between different medical specialists such as pediatricians, endocrinologists, ophthalmologists and optometrists, said study author Dr. Joshua Stein of the University of Michigan Kellogg Eye Center in Ann Arbor.

More research is needed on new technologies which might render ophthalmic screening more accessible, such as retinal photography performed in primary care physicians clinics, he told Reuters Health by email.

Diabetic retinopathy is considered the most common microvascular complication of diabetes and is projected to grow at an alarming rate, said Dr. Seema Garg of the University of North Carolina at Chapel Hill, who wrote a commentary accompanying the study.

Visual impairment is detrimental to patients personal independence, economic productivity, employment and overall quality of life, she told Reuters Health by email. The opportunity costs of a lifetime of blindness are enormous.

Socioeconomics, geographical barriers, delayed referrals from primary care doctors, language barriers and cultural barriers also play a part in the screening gap. Retina screening via telemedicine could help address the issue, especially for racial minorities and economically disadvantaged youth, Garg writes in the commentary.

Telemedicine is an emerging strategy for improving screening with remote expert interpretation, she writes. Telemedicine is effective in reaching underserved populations in remote, rural or urban settings where patients may be at risk for more advanced disease.

SOURCE: bit.ly/2nAJHv1 and bit.ly/2nQkjn2 JAMA Ophthalmology, online March 23, 2017.

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

YANGON Myanmar is training up hundreds of midwives in an effort to reduce the number of women who die in childbirth, one of many social policy reforms launched by the country as it emerges from decades of military rule.

Continue reading here:
Youth with diabetes need vision loss screening | Reuters - Reuters

Read More...

Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35% – Men’s Health

April 1st, 2017 9:50 pm

Men's Health
Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35%
Men's Health
After analyzing the food consumption of 3,349 people at high risk of heart disease but without type 2 diabetes, they discovered that those who ate about 3 servings a week of lentils, chickpeas, beans, and peas were 35 percent less likely to develop ...
Eat legumes to reduce your risk of type 2 diabetes by 35%Daily Mail
Eat legumes to cut the risk of Type 2 diabetesHindustan Times
Suffering from diabetes? Eating legumes may helpEconomic Times
Malay Mail Online -Diabetes.co.uk
all 14 news articles »

Here is the original post:
Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35% - Men's Health

Read More...

Metformin in breast cancer – Nature.com

April 1st, 2017 9:50 pm
Metformin in breast cancer
Nature.com
A new study published in the Journal of Clinical Oncology reports that metformin improves the prognosis of patients with HER2-positive, hormone receptor (HR)-positive breast cancer and diabetes mellitus. The phase III randomized ALTTO trial included ...

Visit link:
Metformin in breast cancer - Nature.com

Read More...

New therapies show promise in treating diabetes – ModernMedicine

April 1st, 2017 9:50 pm

Diabetes medications were the most expensive traditional therapy drugs in 2016, with an overall trend of 19.4%, according to the latest Express Scripts drug trend report. This positive trend is reflective of increases in both utilization and cost.

Heres how pipeline developments could change the landscape.

Pipeline treatments

Peterson

While I do not see any game-changing medications within the diabetes class that will reach the market within the next several years, there are a few updates that we are watching, says Chris Peterson, director in the emerging therapeutics department at Express Scripts.

He points to the continued growth of the sodium-dependent glucose cotransporter-2 (SGLT-2) inhibitor classsparked by the positive cardiovascular outcomes from empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), a previously approved SGLT2 inhibitor. Pipeline SGLT-2 inhibitors include investigational ertugliflozin (Merck and Pfizer) and bexagliflozin (Chugai Pharma), both in phase 3 development at press time. Sotagliflozin (Lexicon Pharmaceuticals),a first-in-class oral dual SGLT-1 and SGLT-2 inhibitor for type 1 and type 2 diabetes, also in phase 3. If approved, it will be the first oral drug approved for type 1 diabetes, a disease that typically has been managed by lifestyle modifications and insulins, says Farrah Wong, PharmD, director, pipeline and drug surveillance at OptumRx.

Wong

The glucagon-like peptide-1 (GLP-1) analog class is also expected to grow, says Peterson. This is driven by cardiovascular outcomes data with liraglutide (Victoza, Novo Nordisk) and the introduction of the fixed-dose combination GLP-1 agonist/long-acting insulin products, insulin glargine and lixisenatide injection (Soliqua 100/3, Sanofi) and insulin degludec/liraglutide (Xultophy, Novo Nordisk).

Semaglutide is a GLP-1 agonist in development for glycemic control in patients with type 2 diabetes. It is being developed as both subcutaneous formulation from Novo Nordisk and oral form from Novartis. If approved, it will be the first oral GLP-1 agonist on the market.

As oral drugs are easier to administer and less invasive than injectable drugs, oral semaglutide may offer these advantages over other GLP-1 agonists, says Wong. Furthermore, type 2 diabetics will have another oral therapeutic option in a class of drugs that thus far were only injectable drugs.

Exenatide osmotic mini-pump (ITCA 650, Intarcia Therapeutics, Inc.) is a subcutaneous implant that continuously delivers the GLP-1 agonist, exenatide, for three months (introductory dose) or six months (maintenance dose) to treat type 2 diabetes. Approval is expected in November 2017, says Peterson.

New insulin products are also expected to receive approval soon, including insulin tregopil (Biocon Ltd.), an oral insulin in phase 2 development for type 1 and type 2 diabetes.

Currently, insulins are either injected or inhaled, says Wong. If an oral insulin product is available, the ease of administration may drive some of the market share to shift from injectable/inhaled insulins to the oral product.

Insulin glargine injection (Basaglar, Eli Lilly/Boehringer Ingelheim) approved last year, was the first follow-on insulin glargine product to treat diabetes. Another follow-on insulin glargine product, known as MK-1293 (Merck/Samsung Bioepis), will be competing as a brand product within the market and is expected to be approved in the second quarter of 2017. Basalog is yet another insulin glargine product currently in phase 3 development; however, it is not yet clear whether the manufacturer, Mylan, will seek approval as a competing brand or as a generic to Lantus (Sanofi). Finally, Sanofi is developing SAR342434, a follow-on protein to Lilly's Humalog (insulin lispro), for the treatment of diabetes mellitus. If approved, it will compete as a brand with the other rapid-acting insulins.

View post:
New therapies show promise in treating diabetes - ModernMedicine

Read More...

‘Killing Leuk:’ Kelly Marre’s book signing April 8 – Mat-Su Valley Frontiersman

April 1st, 2017 9:48 pm

WASILLA I always say my story begins with Logan, Kelly Marre says.

Her first born son, Logan passed away at the age of 11 in 1998 after fighting acute lymphoblastic leukemia (ALL). Nineteen years later, Marre carries his memory everywhere. As an active member in the volunteer community, particularly focusing her efforts on Leukemia and bone marrow registries, Marre states she tries to do everything with purpose.

When God took Logan, it did not compromise my faith. I could have been bitter and cursed his name from a mountaintop. But I didnt. Look around everything is beautiful. Logans story almost 19 years after his death lives on (Sharing her story and her sons) It brings people hope and that is my purpose, Marre says.

Kelly, too, is battling leukemia. Now 22 months into remission, Marre has survived thus far and has a story to share.

Saturday, April 8, from 11am to 2pm is Kelly Marres book signing event. Titled, Killing Leuk, the book chronicles her journey through the stages of Acute myeloid leukemia (AML).

The book-singing event will be inside the new Little Millers Caf off the Palmer-Wasilla Highway. Guests can stroll into the cozy lounge and casually waft through the afternoon with Marre as she sells and signs books and welcomes meaningful conversations. She invites anyone who wants talk about overcoming the challenges of pain and suffering, hoping to a brighter future.

Marres goal is to donate $1 for every book sold. If they all sell that would mean 4,000 books to raise $4,000 to donate to her charities of choice: The Ronald McDonald Foundation, Be the Match (bone marrow registry), the Make-a-Wish Foundation, and the Leukemia & Lymphoma Society.

Nineteen years after her son Logans death, Marres book details her dealings with loss, illness, high hopes and setbacks, hope, strength, and ultimately inspiration; how she kept fighting through every strained step, every clump of hair fallen, each relapse. All with the love and support through faith, friends, family, and the heartbeat of the community.

Logan was pretty famous in our community, Marre said.

If you look back in the Frontiersman archives, you will find stories surrounding Marres family and the impact it had on the community; a living, breathing story arc of love and loss, whirling a dramatic wind of positive momentum, all around.

You know what, we all have stories; we all have circumstances, and we all have pain and weve all had suffering, she said. Its what we do with that its our journey. We were given a journey and its all how we walk that journey that can make our break us.

Both Logan and Kelly were unable to find matches for bone marrow transplants. Both, however, received cord blood units from donated umbilical cords.

The umbilical cord is rich, rich in stem cells. Unfortunately in Alaska we dont have that opportunity and Im trying to change that, Marre said. Thats why I get involved with the be the match bone marrow registry drive. We need to find matches for everybody.

Anyone interested in visiting Kelly Marre is welcome to do stop by this Saturday. It appears Marre and her sons stories have already given people hope. Theres always room for more.

Read the original:
'Killing Leuk:' Kelly Marre's book signing April 8 - Mat-Su Valley Frontiersman

Read More...

If Young Blood Can Combat Aging, It May Be Thanks to Just One Protein – Futurism

April 1st, 2017 9:48 pm

In Brief Studies are being done on the value of replacing older blood with younger blood via transfusions. Other researchers are studying the effects of a certain protein, osteopontin, on blood cell production. 1000 Ways To Live Forever

Society is gradually changing its classification of aging as a natural phenomenon to a disease. We have made strides in our research on preventing and potentially reversing the effects of aging.In addition to the ongoing research in molecular biology ontelomeres, there is the interesting idea of utilizing young blood to combat aging. Ironically, the legends of Dracula might be vindicated in light of new research involving young blood to rehabilitate cognitive abilities in mice, which has inspiredclinical trials that may give patients a chance at beating the Grim Reaper.

Ambrosia, a company inspired by the work done by Stanford University neuroscientistTony Wyss-Coray with parabiosis in mice, charges $8,000 per patient for its human clinical trial ofparabiosis. Although there may be 600 people whotake part in the study transfusing 1.5 liters of plasma with donors between the ages of 16 and 25, thestudy is being done without the blessing of Wyss. He believes that the study does not genuinely represent the science and that, theres just no clinical evidence, and youre basically abusing peoples trust and the public excitement around this.

While Ambrosia is operatingwithout clinical evidence to support the trials, the science behind utilizing young blood in repairing and restoring aged cellular processes is worth taking a look at.

Red and white blood cells are produced from stem cellswithin bone marrow, and as we grow older, our bodys ability to replenish the number of red and white blood cells greatly depletes. Similar to the mouse trials ran by Wyss-Coray, researcherHartmut Geigerand his team at the University of Ulm in Germany looked at the bone marrow in mice at varying ages and determined that older rodents produce very low levels of the protein osteopontin.

Rather than looking at blood transfusions for apossible solution like Wyss-Corays team, Geigers team looked the potential of stem cells to test the importance of the deficient protein.The team introduced fresh stem cells into mice that had little to no osteopontin and noticed that the stem cells aged very quickly. When older stem cells were introduced to a dish with osteopontin and anactivator protein, the stem cells began to propagate blood cells.

While companies like Ambrosia are testing blood transfusions on humans to mimic an experiment that utilized a shared circulatory system between an older mouse and a younger mouse, Geigers team notes that long-term studies must be done on their work to verify the effect of osteopontin on rejuvenating cells completely.

The team is developing a drug with the protein and its activating factor, but they do not promise a fountain of youth. They do believe that there would be benefits for the immune systems of the elderly, which may be better positioned to fight diseases that are linked with cardiovascular agingafter takingthe drug.

While all this talk about immortality is exciting, it might be a while before we can actually reap the benefits of researchers studiesin the way we hope. In the meantime, we can keep dreaming away death.

See more here:
If Young Blood Can Combat Aging, It May Be Thanks to Just One Protein - Futurism

Read More...

Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer – P&T Community

April 1st, 2017 9:48 pm
Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer
P&T Community
Excluding skin cancers, colorectal cancer (CRC) is the third most common cancer diagnosed in men and women in the United States. Overall, the lifetime risk of developing the disease is approximately one in 21 (4.7%) for men and one in 23 (4.4%) for ...

Read more:
Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer - P&T Community

Read More...

Addicted to blindness – The Nation

April 1st, 2017 9:48 pm

As I write these words, the death toll from the blast outside an imambargah in Parachinar has increased to 22. There is no doubt that the number will grow further. A day earlier, a leader of the Ahmedi community, Malik Saleem Latif was brutally killed while on his way to the court. These incidents are exclamation marks and need to be treated seriously.

There is much sadness in these words. As a student in a foreign country, Ive tried very hard to present a peaceful image of Pakistan to the international community. Ive spent hours trying to justify our ruthlessness after 9/11. I have expressed my annoyance at the international audience for not giving the Pakistani culture as much attention as they give to Indian culture. Ive expressed anger when theyve termed something distinctly Pakistani as Indian. Ive expressed sorrow when, after munching on Pakistani delicacies, theyve exclaimed their love for Indian food. I digress. However, the truth is that this has been an unlevel field and Ive tried very hard to have people fall in love with the Pakistan I earnestly love. Of course its been a difficult job and Pakistan hasnt made it any easier.

There is no way to justify any form of violence. There is much to learn from people who find themselves terrorised after a racial slur is thrown in their society. There is even more to embrace from a nation that mourns as one when a single life is wasted. There is much to acknowledge from a community that identifies each other as human and insist thats the only distinction that matters.

Pakistan is a different context. Or, is it? Time and time again, we have reasoned ourselves for our shortfalls. The many, many shortfalls. Weve reasoned to ourselves over our softness towards the monsters that were the Taliban, weve reasoned shamelessly on sainting the murderer Qadri, weve reasoned our disregard for continuing to allow Maulana Abdul Aziz to preach hatred against our mere existence, weve reasoned (or at least Hamza Ali Abbasi has) our failure to see Hafiz Saeed as a terrorist. Time and time again we have reasoned with ourselves for not terming incidents like Parachinar for what they are: sectarian violence. We continue to reason the discrimination and prosecution of the Ahmedi community. There is so much more.

The reaction to such complaints are consistently redundant. Why dont you look at the positives? Why just focus on the negatives? The answer remains the same: cherry picking certain good things out of a murky pond of a country does not prove Pakistan to be a nation of realists. It proves Pakistan to be a nation of foolish optimists, delusional people who are addicted to their blindness.

Irfan Hussain, started his writeup for Nov 20, 2010 by indicating that he realised the nugatory of his pleas and simply wrote to vent his spleen. Dec 25, 2011, Ardeshir Cowasjee bade farewell to his incredible career with these words: Now, old at 85, tired, and disillusioned with a country that just cannot pull itself together in any way and get on with life in this day and age, I have decided to call it a day. This column too caries no burden of expectations with it.

The way to move forward is easy: we have to stop moving forward. We have to be angry when the likes of Chaudry Nisar take the podium and justify the banning of social media. We need to be flabbergasted by Justice Shaukat Aziz who seems to be living under a stone for thinking that social media is all about selfies and pictures of food. We need to put a check to our laziness for refusing to knock sanity into our social psyche.

Why should the people abroad fall in love with Pakistan? Why would investors and entrepreneurs penetrate the market that seeks to eliminate social media; the arena and foundation of countless businesses. Why would anyone have any pity for a country that is bent upon butchering itself by exaggerating differences based on personal beliefs? Why would anyone see Pakistanis as humans when for them a religious deviant is no more a human?

As any foolish does, I too hope for a time when Pakistan will not be what it is today. The country is its own demon and the only way to escape this tragedy is to stop being itself. Till then I shall continue harassing the international audience for not being as delusional as I am, for not romanticising the past as I do, for not being in love with Pakistan like I am.

Go here to see the original:
Addicted to blindness - The Nation

Read More...

Best Master’s Degrees in Biotechnology 2017

April 1st, 2017 9:47 pm

Biotechnology is a top-notch field of study that emerged into the scientific world as a result of revolutions in Biology, Chemistry, Informatics, and Engineering. It is considered to be an applied branch of Biology. Biotechnology helps out this old and respectable field of science keep up with the pace of time and remain competitive in the contemporary world.

With a Master in Biotechnology, students will study the use of living organisms and bioprocesses in technology, engineering, medicine, agriculture and results in all kinds of bioproducts, from genetically modified food to serious cutting-edge devices used to carry out gene therapy. Students in Master in Biotechnology programs may also explore bioinformatics, which is the application of statistics and computer science to the field of molecular biology. Bioinformatics is extremely important for contemporary biological and molecular researches because the data amount there grows by geometric progression and it is necessary to have adequate technology to process it. Bioinformatic methods are widely used for mapping and analyzing DNA and protein samples, as well as for the study of genetics and molecular modeling. Biotechnology and Bioinformatics do a great favour to traditional fields of study, refreshing them with new methods of research, which allows their drastic development, and you can make your contribution with a Master in Biotechnology degree.

Find out about various Master in Biotechnology programs by following the links below. Don't hesitate to send the "Request free information" form to come in contact with the relevant person at the school and get even more information about the specific Master in Biotechnology program you are interested in.

Originally posted here:
Best Master's Degrees in Biotechnology 2017

Read More...

BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC … – ETF Daily News (blog)

April 1st, 2017 9:47 pm

March 31, 2017 9:38am NASDAQ:BBC

From Zacks: After being stressed by the twin attacks of higher drug pricing and increased regulatory scrutiny, the biotech sector has made a strong comeback in the first quarter of 2017.

In fact, BioShares Biotechnology Clinical Trials ETF (BBC Free Report) tops the list of the best performing ETFs of the quarter, with impressive returns of about 27.4%. BBC carries a Zacks ETF Rank of 3 or Hold rating with a High risk outlook.

The surge in the fund was largely driven by cheap valuation, robust earnings results and a slew of positive actions taken by the President. In particular, Trump promised to reduce federal regulations by 7580% and streamline the Food & Drug Administration (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trumps proposed tax reforms and cash repatriation policy are also supporting the rally (read: Top ETF Stories of Q1 from Wall Street).

Apart from these, encouraging industry trends including the possibility of increased M&A activity, an accelerated pace of innovation, promising drug launches, growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, the growing middle class, an insatiable demand for new drugs, and ever-increasing health care spending are fueling growth in the sector.

Lets take a closer look at the fundamentals of BBC and its performance.

BBC in Focus

This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trials stage. This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index. BBC is a small cap centric fund, having amassed $24.4 million in its asset base. It charges 85 bps in fees per year from investors and trades in light average daily volume of around 14,000 shares.

Holding 70 stocks in its basket, it is widely spread out across various components with none holding more than 3.34% share. Though almost all the stocks in the funds portfolio delivered strong returns, a few were the real stars that more than doubled their size (read: Hit ETFs & Stocks from the Top Sector of February).

Below we have highlighted those five best-performing stocks in the ETF with their respective positions in the funds basket:

Best Performing Stocks of BBC

Esperion Therapeutics Inc. (ESPR Free Report) : The stock has surged about 185% so far this year and carries a Zacks Rank #3 with solid Industry rank in the top 39%. Most of the gains came on hopes of the Food and Drug Administrations (FDA) approval to the cholesterol-lowering medicine bempadoic acid. However, Esperion saw its earnings estimates deteriorating from a loss of $3.46 to a loss of $6.27 for this year over the past 90 days. It also has an unfavorable VGM Style Score of F. ESPR occupies the top spot in the funds basket with 3.3% of the total assets (see: all the Health care ETFs here).

Global Blood Therapeutics Inc. (GBT Free Report) : This stock takes the second position in the funds basket with 2.8% allocation. It has also delivered incredible returns of 169% in the first quarter on rumors of the takeover of a big pharma name like Novo Nordisk (NVO). The stock saw its earnings estimates moving from a loss of $2.89 to a loss of $2.83 for this year over last the 90 days. Further, it belong to a solid Industry with a Zacks Rank in the top 43%. The stock has a Zacks Rank #3 with a VGM Style Score of F.

TG Therapeutics Inc. (TGTX Free Report) : It currently has a Zacks Rank #3 with a VGM Style Score of F. The stock soared nearly 150% in the first quarter with most upside coming after positive study results from its phase 3 clinical trial of treatment for high-risk leukemia patients. However, TG Therapeutics saw negative earnings estimate revision of a nickel for the current year over the past 30 days and has an ugly Zacks Industry rank in the bottom 32%. The stock is the third firm and accounts for 2.7% share in BBC (read: Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs).

Cara Therapeutics Inc. (CARA Free Report) : The stock has been climbing since the start of the year and has gained about 105.5% this quarter on the pending trial results of its lead drug candidate. It hit a new one-year high of $20.90 in the last trading session after the company announced positive results from part A of a phase 2/3 trial for chronic kidney disease-associated pruritus. Cara Therapeutics has a solid Zacks Industry rank in the top 43%. However, it has a Zacks Rank #4 (Sell) with a VGM Style Score of F. The stock occupies the fourth position in the funds portfolio, making up for 2.5% share.

NewLink Genetics Corporation (NLNK Free Report) : This stock takes the seventh spot in the funds basket with 2.2% of assets. It has doubled this quarter but saw negative earnings estimate revision of $1.21 for this year over the past 90 days. NewLink Genetics currently has a Zacks Rank #3 with a VGM Style Score of F and solid Zacks Industry rank in the top 43%.

The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) was unchanged in premarket trading Friday. Year-to-date, BBC has gained 25.75%, versus a 5.59% rise in the benchmark S&P 500 index during the same period.

BBC currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #23 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Zacks Research.

Tags: biotech Equity Health Care NASDAQ:BBC Zacks

Categories: NASDAQ:BBC

Read the original:
BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC ... - ETF Daily News (blog)

Read More...

Lady Gaga Arthritis Magazine Cover Hip Pain – Refinery29 – Refinery29

April 1st, 2017 9:46 pm

Longtime Little Monsters might not be surprised to see their Mother Monster talking about hip pain, though. The 31-year-old was forced to cancel the remainder of her Born This Way Ball world tour in February 2013 after suffering a massive joint tear and hip breakage requiring surgery. Initially, she thought the pain was the result of only a labral tear and an inflammatory joint condition called synovitis, but tests revealed her hip was broken as well. "Nobody knew, and I havent even told the fans yet," she revealed to Women's Wear Daily that July. "[The MRIs showed] giant craters, a hole in my hip the size of a quarter, and the cartilage was just hanging out the other side of my hip. She added, "The surgeon told me that if I had done another show I might have needed a full hip replacement. I would have been out at least a year, maybe longer."

See the original post here:
Lady Gaga Arthritis Magazine Cover Hip Pain - Refinery29 - Refinery29

Read More...

Arthritis in the youth – Daily News & Analysis

April 1st, 2017 9:46 pm

When we think of arthritis, we believe of the elderly it affects. But age is not the only factor for arthritis; it can affect young and old alike. Data source? The number of cases of arthritis among youth has seen an increase in last two-three.

Arthritis may result from an injury to a joint, inflammatory disease or an infection. The most common causes of arthritis affecting young people include Juvenile Chronic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Haemophilia, infections like Tuberculosis, etc. It often presents as pain and swelling in the joints. It disturbs the normal life of a person. He or she is unable to do his or her basic activities like walking, running, climbing and even sitting. It not only leads to the restriction of movement but also make the life of the person painful.

The human body has 68 joints, and all of them are susceptible to arthritis. However, the disease, once diagnosed, can be controlled by prompt and continued treatment. Arthritis strikes more women than men. And if intervention is not sought in time, it can impact the chances of improvement in symptoms like stiffness when waking and joint pain during the day, swelling around joints, reduced activity level does not improve over time.

Treatment depends on the type of arthritis and the various symptoms associated with it. Lifestyle changes can also help. Usually, treatment includes drugs to control the pain and inflammation and also stronger painkillers and steroids to alter the immune system. Then there are various types of injections (like steroids, platelet-rich plasma etc.) used for painful joints. For rheumatoid arthritis, it is crucial for the patient to follow an exercise regime along with it a good diet.

Platelet-rich plasma (PRP) is a concentrated extract of platelets derived from patient's own blood, by centrifugation. Platelets have high concentration of various growth factors which help in healing of tissues and hence PRP is now considered as a novel and new treatment option for arthritic patients.

Rest, relaxation, medication and appropriate use of joints are also other forms of treatment. Apart from this, there are other natural medications (haldi pack for temperory relief) also. However, if the problem is severe, surgery like arthroscopy or joint replacement may be required. Recently, various cartilage restoration techniques like cartilage transplantation have emerged as a biological solution for arthritic patients. Cartilage transplantation is a biological treatment where the cultured chondrocyte cells or concentrated mesenchymal cells are injected to the damaged areas of joint. It thus repairs the damaged cartilage of joint and not only provides pain relief by postpone the need for joint replacement surgery.

These help the person in leading a normal life, and also do all the activities which earlier had become a burden. In short, they make the lives of arthritis patient much easier.

It is also important to lose weight to lessen the burden on the joints. Do exercise that doesn't damage joints like low-impact biking, swimming, along with yoga, walking (if it is not too fast), and weightlifting (as long as it is not stressful).

The author is a senior consultant orthopaedic surgeon at Indraprastha Apollo Hospitals, New Delhi and founder president of Arthritis Care Foundation.

Did you like this article? Do send us your feedback to dnaofhealth@gmail.com

Read more:
Arthritis in the youth - Daily News & Analysis

Read More...

Antibody May Help Deliver Better Prognosis, Treatments for Rheumatoid Arthritis – Healthline

April 1st, 2017 9:46 pm

Rheumatoid arthritis is a painful, debilitating autoimmune disease.

That makes it a difficult condition to treat.

But now, researchers have found that specific antibodies in certain people with rheumatoid arthritis (RA) may provide more treatment options and a better outlook for people with the disease.

In some but not all people with RA, there are antibodies formed that target a protein in joint cartilage called collagen II.

These antibodies often play a role in increasing inflammation in the earlier stages of RA.

Read more: Rheumatoid arthritis and stem cell treatment

In the past, researchers have concluded that the highest amounts of collagen antibodies are usually detected at the time of an RA diagnosis.

These levels most often decrease during the first year of RA disease activity.

But a recent study out of Uppsala University in Sweden concluded that antibodies against the cartilage protein collagen II are associated with a good outlook.

Researchers said people with RA who have more of these antibodies often do better when it comes to treatments, the management of symptoms, and how disabling their symptoms become.

This study followed a group of people with RA over the course of five years to look at the suspected correlation between collagen antibodies and disease advancement.

What they found could prove vital as a prognostic tool and help to further individualize and implement targeted treatments.

Analyzing these antibodies, in combination with other relevant antibodies, could be used for predicting prognosis and choosing therapy for rheumatoid arthritis patients, Dr. Johan Rnnelid, lead researcher on the study, said in a press release.

Vivek Anand Manivel, a PhD student at the Department of Immunology, Genetics and Pathology, and a lead author of the study, also offered a public statement to the press: We found that patients with collagen antibodies showed increased signs of inflammation during the first six months after diagnosis, after this there was no difference compared to patients without any collagen antibodies. We also discovered that the presence of collagen antibodies at the time of diagnosis was associated with a better prognosis.

Read more: Can cancer medications bring on rheumatoid arthritis?

What this means for people with RA is that treatments may become better-tailored to them moving forward, depending on the antibody presence and activity.

RA is a complex disease that manifests itself differently from person to person.

Since disease activity is so unpredictable, any assistance in figuring out prognosis or a better therapeutic approach could be of importance to the rheumatology community.

In all, our findings suggest that a combined analysis of antibodies against collagen and antibodies against citrullinated peptides could be a new tool for predicting the disease course and perhaps also for choosing therapy in newly diagnosed RA patients, said Rnnelid.

Currently, anti-cyclic citrullinated peptide (anti-CCP) is often used as an indicator for RA disease activity, alongside rheumatoid factors.

Now, doctors can look at the collagen II antibodies as well when determining disease severity and thus, a more robust and detailed plan for treatment and disease management.

Read more: Green tea as a treatment for rheumatoid arthritis

Original post:
Antibody May Help Deliver Better Prognosis, Treatments for Rheumatoid Arthritis - Healthline

Read More...

Page 1,040«..1020..1,0391,0401,0411,042..1,0501,060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick